Mabtech, a Swedish life science tools company specializing in high-quality immunoassays, reagents, and instrumentation, today announced a strategic collaboration with Sai Life Sciences, a leading ...

Pediatric EBGLYSS trial meets endpoints in dermatitis care; Broader immunology portfolio gains attention beyond metabolic therapies; Recent share movement frames respo ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactu ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiate ...

The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients ...